刚果民主共和国自5月中旬爆发埃博拉疫情以来，已造成超3000人死亡1。其中5岁以下儿童的病死率超过60%1。无国界医生组织指出，这一高死亡率的主要原因并非疾病本身，而是缺乏针对儿童患者的治疗用药方案和相关医学信息1。
进行中的EBO-PEP研究项目暴露了这一问题的严重性。该研究原本排除了体重低于30公斤（约12岁以下）的儿童参与1，体重低于20公斤（约6岁以下）的儿童更是被完全排除在新型抗病毒药物治疗之外1。无国界医生组织在《柳叶刀》杂志发表评论，呼吁"儿童必须成为埃博拉治疗和预防研究的中心"1。
2020年，全球儿科制剂加速器网络在世界卫生组织支持下成立，旨在加速儿童友好型药物的开发和供应1。
An Ebola outbreak that began in the Democratic Republic of Congo in mid-May has claimed over 3,000 lives, with children under five experiencing a fatality rate exceeding 60% 1. However, Médecins Sans Frontières has identified that the elevated mortality among children stems not primarily from the disease itself, but rather from the absence of pediatric-specific treatment protocols and information 1.
A significant barrier to equitable care emerged through the EBO-PEP research trial, which launched in mid-July with notably restrictive enrollment criteria 1. The trial originally excluded children weighing less than 30 kilograms—approximately those under 12 years old—while those under 20 kilograms, roughly six years of age, faced complete exclusion from access to newly developed antiviral medications 1. Médecins Sans Frontières published a commentary in The Lancet asserting that "children must be at the center of Ebola treatment and prevention research," highlighting the urgent need to rectify this disparity 1. In response to systemic gaps in pediatric pharmaceutical development, the Global Pediatric Formulations Accelerator Network was established in 2020 with World Health Organization support to expedite the creation and availability of child-friendly medications 1.
评论
还没有评论，欢迎留下第一条。